Design Therapeutics, Inc. (NASDAQ: DSGN) is a Healthcare company (Biotechnology) with a market capitalization of $630M. The Maz Rating grades it against the other companies in its sector.
Design Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.84, Design Therapeutics, Inc. trades at 3.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -35.5%, return on invested capital of -40.2% and a free cash flow yield of -9.4%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 16.78. Over the past 52 weeks the share price ranged from $7.25 to $17.25, with a beta of 1.74.
Design Therapeutics, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 4 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Design Therapeutics, Inc. (DSGN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 26.9% / 30% · Interest income / Revenue 194200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 26.9% / 33% · Receivables / Mkt Cap (36m) 0.22% / 49% · Interest income / Revenue 194200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 26.9% / 33.33% · Receivables / Mkt Cap (24m) 0.22% / 33.33% · Interest income / Revenue 194200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.6% / 33.33% · Receivables / Avg Assets (4Q) 0.79% / 33.33% · Interest income / Revenue 194200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.2% / 33.33% · (Cash+Recv) / Total Assets 97.0% / 33.33% · Interest income / Revenue 194200000.0% / 5% | Fail |
No. As of September 2026, Design Therapeutics, Inc. (DSGN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Design Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 194200000.0% of each dividend: Design Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.